Mucosal Protective Agents Prevent Exacerbation of NSAID
... (10). PAS-positive area in the mucosa was measured using ImageJ 1.4 (National Institutes of Health, Bethesda, MD) according to the method described in our previous paper (Yoda et al., 2010). Statistical Analysiss. All data are expressed as the mean 6 S.E.M. Differences between groups were analyzed ...
... (10). PAS-positive area in the mucosa was measured using ImageJ 1.4 (National Institutes of Health, Bethesda, MD) according to the method described in our previous paper (Yoda et al., 2010). Statistical Analysiss. All data are expressed as the mean 6 S.E.M. Differences between groups were analyzed ...
PART II - United Nations Office on Drugs and Crime
... disorders. Such services are aimed at stopping or reducing the effects of acute intoxication, managing withdrawal symptoms during detoxification, preventing relapse and deali ng with longterm psychological and behavioural symptoms. “Substance-related disorders” include abuse and dependence, as well ...
... disorders. Such services are aimed at stopping or reducing the effects of acute intoxication, managing withdrawal symptoms during detoxification, preventing relapse and deali ng with longterm psychological and behavioural symptoms. “Substance-related disorders” include abuse and dependence, as well ...
antihistamines in allergic disease
... H1 antihistamines are classified into the older, or firstgeneration, antihistamines, and the newer, or secondgeneration, antihistamines. The main differences between the two generations of drugs are their propensity to cause central nervous system (CNS) sideeffects. The commonly used members of thes ...
... H1 antihistamines are classified into the older, or firstgeneration, antihistamines, and the newer, or secondgeneration, antihistamines. The main differences between the two generations of drugs are their propensity to cause central nervous system (CNS) sideeffects. The commonly used members of thes ...
(Cannabis genus) for use as animal feed
... that this corresponds “to 0.06 mg/kg bw calculated for the highest individual body weight.” EIHA suggests that a LOEL for THC should be based on two doses a day, since effects after oral administration usually last about 4-6 hours and the daily dose of THC in food is usually not consumed in one meal ...
... that this corresponds “to 0.06 mg/kg bw calculated for the highest individual body weight.” EIHA suggests that a LOEL for THC should be based on two doses a day, since effects after oral administration usually last about 4-6 hours and the daily dose of THC in food is usually not consumed in one meal ...
adderall xr - Shire Canada
... Amphetamines have a potential for abuse, misuse, dependence, or diversion for non-therapeutic uses that physicians should consider when prescribing this product( see PRECAUTIONS, Dependence Liability.) The misuse of amphetamines may cause serious cardiovascular adverse events and sudden death. Pre-e ...
... Amphetamines have a potential for abuse, misuse, dependence, or diversion for non-therapeutic uses that physicians should consider when prescribing this product( see PRECAUTIONS, Dependence Liability.) The misuse of amphetamines may cause serious cardiovascular adverse events and sudden death. Pre-e ...
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
... Athletes must be aware that this medicine may cause a positive reaction to ‘anti-doping’ tests. As with other opioids, caution is requested in patients using buprenorphine and having head injury, increased intracranial pressure, hypotension, prostatic hypertrophy or urethral stenosis. This product s ...
... Athletes must be aware that this medicine may cause a positive reaction to ‘anti-doping’ tests. As with other opioids, caution is requested in patients using buprenorphine and having head injury, increased intracranial pressure, hypotension, prostatic hypertrophy or urethral stenosis. This product s ...
Catechol-O-methyltransferase val met genotype
... absence of pharmacologic manipulation, consistent with what has been reported on other measures of cognition. In addition, we hypothesized that val/val carriers would exhibit a greater improvement in performance after d-amphetamine than met/met carriers. We did not expect that these genotypic groups ...
... absence of pharmacologic manipulation, consistent with what has been reported on other measures of cognition. In addition, we hypothesized that val/val carriers would exhibit a greater improvement in performance after d-amphetamine than met/met carriers. We did not expect that these genotypic groups ...
the PDF
... et al., 1996), associated with Lewy body dementia (Moutoussis & Orrell, 1996), and in cerebral palsy in children (Buonaguro et al., 2005; Scheinberg et al., 2006) and adults (Krach, 2009). A very important breakthrough was achieved by administration of baclofen directly into the CSF via an implanted ...
... et al., 1996), associated with Lewy body dementia (Moutoussis & Orrell, 1996), and in cerebral palsy in children (Buonaguro et al., 2005; Scheinberg et al., 2006) and adults (Krach, 2009). A very important breakthrough was achieved by administration of baclofen directly into the CSF via an implanted ...
First clinical data of the neuroprotective effects of nasal insulin
... clinical pilot trials in patients with AD and mild cognitive impairment. Because insulin has powerful effects on blood sugar levels, a new technique was used by which insulin is applied as a spray. This method avoids high levels of insulin in the periphery and makes use of the transport system, via ...
... clinical pilot trials in patients with AD and mild cognitive impairment. Because insulin has powerful effects on blood sugar levels, a new technique was used by which insulin is applied as a spray. This method avoids high levels of insulin in the periphery and makes use of the transport system, via ...
RIVM rapport 370030002 Trends in drug substances detected in
... A total of 256 suspect weight-loss products were included in the collective database, 83% of which were dietary supplements and 17% were medicines confiscated outside the official distribution chain. In 90% of the weight-loss products one or more drug substances were identified. A total of 20 differ ...
... A total of 256 suspect weight-loss products were included in the collective database, 83% of which were dietary supplements and 17% were medicines confiscated outside the official distribution chain. In 90% of the weight-loss products one or more drug substances were identified. A total of 20 differ ...
Lecture notes on Toxicology
... chapters are concerning the basic toxicological testing methods, which planned specifically as a subject matter to the ...
... chapters are concerning the basic toxicological testing methods, which planned specifically as a subject matter to the ...
Studies on Variability in Olanzapine Disposition
... than men. However, the higher C/D ratio for OLA in women was statistically significant only in the non-smoking group. Non-smokers had significantly higher C/D ratio for OLA than smokers. Smokers received significantly higher daily doses of OLA than non-smokers. In the group with reported ADRs, the s ...
... than men. However, the higher C/D ratio for OLA in women was statistically significant only in the non-smoking group. Non-smokers had significantly higher C/D ratio for OLA than smokers. Smokers received significantly higher daily doses of OLA than non-smokers. In the group with reported ADRs, the s ...
Analysis Reveals that CPX-351 Shifts the Exposure of Cytarabine
... CPX-351 is a liposomal formulation co-encapsulating Cyt and Daun, that delivers the drugs in vivo at a 5:1 molar ratio shown to be synergistic preclinically. Clinically, CPX-351 has provided evidence of promising improvements in patient outcomes, most notably in elderly newly diagnosed high risk (se ...
... CPX-351 is a liposomal formulation co-encapsulating Cyt and Daun, that delivers the drugs in vivo at a 5:1 molar ratio shown to be synergistic preclinically. Clinically, CPX-351 has provided evidence of promising improvements in patient outcomes, most notably in elderly newly diagnosed high risk (se ...
Ferrario A, Kanavos P, Managed entry agreements for pharmaceuticals: the European experience. EMiNet, Brussels, Belgium
... reimbursement lists need to demonstrate that their drugs can provide additional benefit in relation to current therapies and value-for-money in order to obtain coverage. Data and the overall evidence base available at registration are often insufficient to accurately estimate the clinical and cost-e ...
... reimbursement lists need to demonstrate that their drugs can provide additional benefit in relation to current therapies and value-for-money in order to obtain coverage. Data and the overall evidence base available at registration are often insufficient to accurately estimate the clinical and cost-e ...
GYNO-DAKTARIN™ Janssen Pharma
... Once daily before bedtime, insert one vaginal capCOMPOSITION sule deeply into the vagina. This is best done in the GYNO-DAKTARIN Cream: Each gram contains reclining position. Repeat this procedure for 7 days. 20 mg of the active substance miconazole nitrate. The treatment can be shortened by beginni ...
... Once daily before bedtime, insert one vaginal capCOMPOSITION sule deeply into the vagina. This is best done in the GYNO-DAKTARIN Cream: Each gram contains reclining position. Repeat this procedure for 7 days. 20 mg of the active substance miconazole nitrate. The treatment can be shortened by beginni ...
Safe Handling of Hazardous Drugs
... A hazardous drug is any drug identified as hazardous or potentially hazardous by the National Institute for Occupational Safety and Health (NIOSH) on the basis of at least one of the following six criteria: carcinogenicity, teratogenicity or developmental toxicity, reproductive toxicity in humans, o ...
... A hazardous drug is any drug identified as hazardous or potentially hazardous by the National Institute for Occupational Safety and Health (NIOSH) on the basis of at least one of the following six criteria: carcinogenicity, teratogenicity or developmental toxicity, reproductive toxicity in humans, o ...
Pharmacological Treatment of Post-Anesthetic Shivering: An Educational Outreach Project.
... II study included 60 patients from both genders undergoing various surgeries. The included patients were ASA (American Society of Anesthesiologists) grade I, II, or III patients and received regional anesthesia. An ASA I patient is a normal healthy person. ASA II patients have mild systemic disease ...
... II study included 60 patients from both genders undergoing various surgeries. The included patients were ASA (American Society of Anesthesiologists) grade I, II, or III patients and received regional anesthesia. An ASA I patient is a normal healthy person. ASA II patients have mild systemic disease ...
Opposite effects of MDMA
... systolic blood pressure Philosophical doctor (Dr. Phil. II) tetrahydrocannabinol serious adverse event selective serotonin uptake inhibitor state-trait anxiety inventory standard deviation Plasma eliminiation half-life time to reach Cmax visual analogue scale ...
... systolic blood pressure Philosophical doctor (Dr. Phil. II) tetrahydrocannabinol serious adverse event selective serotonin uptake inhibitor state-trait anxiety inventory standard deviation Plasma eliminiation half-life time to reach Cmax visual analogue scale ...
Alprazolam withdrawal and tolerance measured in the social conflict
... A three-way repeated measures ANOVA showed a significant effect of treatment [F(2,97)=7.652, P<0.001], duration of treatment [F(4,194)=5.109, P=0.001] and observation period [F(2,97)=6.522, P=0.002] in the number of aggressive acts (attacks, threats, tail rattles). Next, a three-way repeated measure ...
... A three-way repeated measures ANOVA showed a significant effect of treatment [F(2,97)=7.652, P<0.001], duration of treatment [F(4,194)=5.109, P=0.001] and observation period [F(2,97)=6.522, P=0.002] in the number of aggressive acts (attacks, threats, tail rattles). Next, a three-way repeated measure ...
GHB, GBL and 1,4-BD Addiction - Trimbos
... uncontrolled, and sometimes substantial higher than expected, concentrations or might still contain a considerable amount of GBL for instance. This could have profound effects on its potency and abuse liability. Also, combined use of alcohol and other CNS depressants is strongly discouraged in narco ...
... uncontrolled, and sometimes substantial higher than expected, concentrations or might still contain a considerable amount of GBL for instance. This could have profound effects on its potency and abuse liability. Also, combined use of alcohol and other CNS depressants is strongly discouraged in narco ...
Polysubstance dependence
A person with polysubstance dependence is psychologically addicted to being in an intoxicated state without a preference for one particular substance. Although any combination of three drugs can be used, studies have shown that alcohol is commonly used with another substance. This is supported by one study on polysubstance use that separated participants who used multiple substances into groups based on their preferred drug. The three substances were cocaine, alcohol, and heroin, which implies that those three are very popular. Other studies have found that opiates, cannabis, amphetamines, hallucinogens, inhalants and benzodiazepines are often used in combination as well. The results of a long-term or longitudinal study on substance use led the researchers to observe that excessively using or relying on one drug increased the probability of excessively using or relying on another drug.